NCT02874989View on ClinicalTrials.gov

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 16, 2016

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

Dasatinib + Quercetin

DRUG

Placebo

Trial Locations (2)

27157

Wake Forest Baptist Health, Winston-Salem

78245

University of Texas Health Science Center, San Antonio

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

The University of Texas Health Science Center at San Antonio

OTHER

lead

Wake Forest University Health Sciences

OTHER